查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611170

HIV 临床试验市场规模、份额、趋势分析报告：按阶段、试验设计、申办者、地区、细分市场预测，2025-2030 年

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Sponsor, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

HIV 临床试验市场成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球HIV临床试验市场规模将达到21.1亿美元，2025年至2030年复合年增长率为5.8%。该市场的主要驱动因素是爱滋病毒疫苗临床试验数量的增加、爱滋病毒临床试验研发活动的增加以及对爱滋病毒感染的认识不断提高，从而导致参与临床试验的患者数量不断增加。在 COVID-19 大流行期间，市场成长停止。

HIV/爱滋病临床试验数量的下降是由于政府为预防 COVID-19 而实施的居家令，导致临床试验取消和延迟。它还包括患者招募的中断、临床试验进行的障碍以及快速研究开发疫苗和药物以预防在 HIV 临床试验中产生有害影响的 COVID-19。然而，透过临床实验试验中心、监管机构和政府机构采取的策略措施，这些影响已大大减少。

据世界卫生组织称，2020 年约有 3,770 万人感染爱滋病毒。为了减少这一数字，生物技术和製药公司正在增加资金和合作伙伴关係。此外，各国政府正在加强努力寻找治疗方法并传播对该疾病的认识。例如，2021 年 10 月，Samsung BioLogics 与 Enzolytics Inc. 合作。该合作旨在生产抗 HIV 和抗 SARS-CoV-2 单株抗体疗法。

然而，缺乏对爱滋病毒临床研究试验和预防治疗方法的认识是阻碍该市场成长的因素。根据 BioMed Central Ltd. 的欧洲报告，在 467 名参与者中，大约三分之一的人不知道自己感染了爱滋病毒。因此，对该疾病的无知和缺乏认识可能会阻碍爱滋病毒临床试验的参与。

HIV 临床试验市场报告亮点

  • 2024年，III期在HIV临床试验产业占据主导地位，占销售份额的30.0%。 I 期试验有助于评估药物在不同剂量水平下的安全性和毒性，并确定药物的药物动力学。
  • 2024年，介入试验领域在HIV临床试验产业中占据主导地位，占销售份额的69.8%。
  • 2024年，製药和生物製药公司细分市场占据最大市场占有率。
  • 北美HIV临床试验市场主导全球市场，2024年占最大份额，达47.3%。这是由于该地区正在进行的爱滋病毒临床试验数量增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 HIV 临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章 HIV 临床试验市场：阶段、估计与趋势分析

  • 细分仪表板
  • 全球爱滋病毒临床试验市场：相变分析
  • 2018-2030年全球HIV临床试验规模及趋势分析（分阶段）
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章 HIV 临床试验市场：试验设计、评估与趋势分析

  • 细分仪表板
  • 全球爱滋病毒临床试验市场：研究设计变异分析
  • 2018-2030年全球HIV临床试验规模及趋势分析（依试验设计）
  • 干预试验
  • 观察测试
  • 扩大访问考试

第六章 HIV 临床试验市场：申办者、估算与趋势分析

  • 细分仪表板
  • 全球爱滋病毒临床试验市场：申办者变异分析
  • 2018-2030年全球HIV临床试验规模及趋势分析（依申办单位）
  • 製药和生物製药公司
  • 非营利组织
  • 其他的

第七章 HIV 临床试验市场：区域估计与趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • PPD Inc.
    • IQVIA Inc.
    • Parexel International Corporation
    • ICON plc
    • Syneos Health
    • WuXi AppTec
    • Janssen Global Services, LLC
    • Gilead Sciences, Inc.
    • Bionor Holding AS
    • Charles River Laboratories
    • GSK plc.
    • SGS SA
Product Code: GVR-4-68039-955-8

HIV Clinical Trials Market Growth & Trends:

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights:

  • In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.
  • In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.
  • The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.
  • North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. HIV Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising drug approvals and new product launches
      • 3.2.1.2. Increasing R&D initiatives by biotechnology & pharmaceutical companies
      • 3.2.1.3. Increasing incidence of HIV
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of awareness and access to treatment for HIV Infection
      • 3.2.2.2. Stringent regulations
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. HIV Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global HIV Clinical Trials Market: Phase Movement Analysis
  • 4.3. Global HIV Clinical Trials Size & Trend Analysis: by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global HIV Clinical Trials Market: Study Design Movement Analysis
  • 5.3. Global HIV Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global HIV Clinical Trials Market: Sponsor Movement Analysis
  • 6.3. Global HIV Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Non-Profit Organizations
    • 6.5.1. Non-profit organizations market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. HIV Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. PPD Inc.
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. IQVIA Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Parexel International Corporation.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. ICON plc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Syneos Health
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. WuXi AppTec
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Janssen Global Services, LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Gilead Sciences, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bionor Holding AS
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Charles River Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. GSK plc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SGS SA
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Service benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global HIV Clinical Trials, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 5 Global HIV Clinical Trials, by Services Type, 2018 - 2030 (USD Million)
  • Table 6 Global HIV Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 9 North America HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 10 North America HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 11 U.S. HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 U.S. HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 14 Canada HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Canada HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 17 Mexico HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Mexico HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 20 Europe HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Europe HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 23 Europe HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 24 UK HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 25 UK HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 26 UK HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 27 Germany HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Germany HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 29 Germany HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 30 France HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 31 France HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 32 France HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 33 Italy HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Italy HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 35 Italy HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 36 Spain HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 37 Spain HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 38 Spain HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 39 Denmark HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Denmark HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 41 Denmark HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 42 Sweden HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 43 Sweden HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 44 Sweden HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 45 Norway HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Norway HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 47 Norway HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 52 Japan HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 53 Japan HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 54 Japan HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 55 China HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 56 China HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 57 China HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 58 Japan HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 59 Japan HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 60 Japan HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 61 China HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 62 China HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 63 China HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 64 India HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 65 India HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 66 India HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 67 Thailand HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 68 Thailand HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 69 Thailand HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 70 South Korea HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 71 South Korea HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 72 South Korea HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 73 Australia HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 74 Australia HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 75 Australia HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 76 Latin America HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 77 Latin America HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Latin America HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 79 Latin America HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 80 Brazil HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 81 Brazil HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 82 Brazil HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 83 Argentina HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 84 Argentina HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 85 Argentina HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 87 Middle East & Africa HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 88 Middle East & Africa HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 89 Middle East & Africa HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 90 South Africa HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 91 South Africa HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 92 South Africa HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 96 UAE HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 97 UAE HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 98 UAE HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 99 Kuwait HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 100 Kuwait HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 101 Kuwait HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 HIV Clinical Trials Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 HIV Clinical Trials Market snapshot
  • Fig. 11 HIV Clinical Trials Market driver impact
  • Fig. 12 HIV Clinical Trials Market restraint impact
  • Fig. 13 HIV Clinical Trials Market: Phase takeaways (USD Million)
  • Fig. 14 HIV Clinical Trials Market: Phase movement analysis
  • Fig. 15 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 16 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 17 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 18 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 19 HIV Clinical Trials Market: Study design takeaways (USD Million)
  • Fig. 20 HIV Clinical Trials Market: Study design movement analysis
  • Fig. 21 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 22 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 23 Expanded access studies market, 2018 - 2030 (USD Million)
  • Fig. 24 HIV Clinical Trials Market: Sponsor takeaways (USD Million)
  • Fig. 25 HIV Clinical Trials Market: Sponsor movement analysis
  • Fig. 26 Pharmaceutical & biopharmaceutical companies' market, 2018 - 2030 (USD Million)
  • Fig. 27 Non-profit organizations market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional outlook, 2024 & 2030
  • Fig. 31 North America HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 36 UK HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 38 France HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 China HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 India HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East & Africa HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 Market participant categorization